Circulating tumor DNA and bone marrow minimal residual disease negativity confers superior outcome for multiple myeloma patients

Sridurga Mithraprabhu; John Reynolds; Hang Quach; Noemi Horvath; Ian Kerridge; Tiffany Khong; Brian Gm Durie; Andrew Spencer

doi:10.3324/haematol.2023.283831

Circulating tumor DNA and bone marrow minimal residual disease negativity confers superior outcome for multiple myeloma patients

Haematologica. 2024 Mar 1;109(3):974-978. doi: 10.3324/haematol.2023.283831.

Authors

Sridurga Mithraprabhu¹, John Reynolds², Hang Quach³, Noemi Horvath⁴, Ian Kerridge⁵, Tiffany Khong², Brian Gm Durie⁶, Andrew Spencer⁷

Affiliations

¹ Australian Centre for Blood Diseases, Alfred Health - Monash University, Melbourne, Australia; Department of Malignant Haematology and Stem Cell Transplantation, Alfred Hospital, Melbourne. Durga.mithraprabhu@monash.edu.
² Australian Centre for Blood Diseases, Alfred Health - Monash University, Melbourne, Australia; Department of Malignant Haematology and Stem Cell Transplantation, Alfred Hospital, Melbourne.
³ St.Vincent's Hospital, University of Melbourne.
⁴ Royal Adelaide Hospital, Adelaide.
⁵ Royal North Shore Hospital, Sydney.
⁶ Cedars-Sinai Comprehensive Cancer Center, Los Angeles, California.
⁷ Australian Centre for Blood Diseases, Alfred Health - Monash University, Melbourne, Australia; Department of Malignant Haematology and Stem Cell Transplantation, Alfred Hospital, Melbourne. Andrew.spencer@monash.edu.

No abstract available

MeSH terms

Bone Marrow
Circulating Tumor DNA*
Humans
Multiple Myeloma* / therapy
Neoplasm, Residual

Substances

Circulating Tumor DNA

Grants and funding

Funding: This study was funded by the International Myeloma Foundation’s Black Swan Research Initiative and philanthropic funding through the Alfred Foundation.